Opendata, web and dolomites

OCProDx

Strategic planning for commercialisation of a multiplexed protein diagnostic (Dx) blood test for Organ-Confined Prostate cancer: OCProDx

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "OCProDx" data sheet

The following table provides information about the project.

Coordinator
ATTUROS LIMITED 

Organization address
address: DRUMMAN EAST WILLIAMSTON WHITEGATE
city: LIMERICK CLARE
postcode: V94 W5TV
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.atturos.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2016-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ATTUROS LIMITED IE (LIMERICK CLARE) coordinator 50˙000.00

Map

 Project objective

In Europe over 400,000 (US >250,000, globally >1M) men are diagnosed with prostate cancer every year and well over half will have intermediate to low risk disease. The vast majority of these men would benefit from active surveillance (AS) - monitoring of disease progression before treatment. But most are treated by surgery, radiation or drugs because existing diagnostic tools do not adequately support the AS vs. treatment decision. For those men on AS the tests do easily allow long term repeated monitoring. The over-treatment of prostate cancer is a widely acknowledged and serious issue: the side effects of treatment are often worse than the disease itself and impact negatively on quality of life. We have discovered, developed and patented a blood protein signature that can discriminate between disease that remains confined to the prostate or has spread beyond it. This multiplexed protein signature, the OCProDx test, has the capacity to support at least three key patient decisions. i) for men newly diagnosed with prostate cancer: the decision between AS and treatment; ii) for men on AS: whether to treat or not, and iii) for those to be treated: which treatment may be the best option. The OCProDx test, will be licensed to a newly founded UCD Spin out company 'Atturos’. The market size is very large, the need significant and the estimated gross profit margin very attractive. We believe there is a compelling opportunity to grow Atturos to develop OCProDx within a commercial setting and deliver it to market. In so doing, Atturos will grow rapidly to create high value EU employment opportunities that will be global in reach. Well-resourced laboratory based studies are currently underway to consolidate the technical performance of OCProDx and validate its clinical performance. In this proposal we seek to engage with key external consultants to develop and produce a detailed business plan for Atturos to commercialise and monetise OCProDx.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OCPRODX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OCPRODX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More